Palovarotene

The FDA approved an oral drug, based on foundational research conducted at CHOP, to treat a rare, severe bone disease. More In The News.

Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

This week’s In the News features new study on measuring vision changes in patients with neurofibromatosis type 1, and other research highlights.